Onco-Innovations Announces Closing of Private Placement
Onco-Innovations (OTCQB:ONNVF) has successfully closed its previously announced non-brokered private placement, raising $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit comprises one common share and one warrant, with warrants exercisable at $2.05 per share until August 13, 2028.
The company will utilize the proceeds for general corporate and working capital purposes, including operational and R&D objectives. Additionally, 2,439 administrative shares were issued to a third party for services related to the placement. All securities are subject to a four-month hold period ending December 14, 2025.
Onco-Innovations (OTCQB:ONNVF) ha completato con successo il collocamento privato non intermediato precedentemente annunciato, raccogliendo $400,000 tramite l'emissione di 243,903 unit脿 a $1.64 per unit脿. Ciascuna unit脿 comprende una azione ordinaria e un warrant, con i warrant esercitabili a $2.05 per azione fino al 13 agosto 2028.
La societ脿 utilizzer脿 i proventi per scopi aziendali generali e per il capitale circolante, inclusi obiettivi operativi e di R&S. Inoltre, sono state emesse 2,439 azioni amministrative a una terza parte per servizi relativi al collocamento. Tutti i titoli sono soggetti a un periodo di blocco di quattro mesi che termina il 14 dicembre 2025.
Onco-Innovations (OTCQB:ONNVF) ha cerrado con 茅xito su colocaci贸n privada no intermediada anunciada anteriormente, recaudando $400,000 mediante la emisi贸n de 243,903 unidades a $1.64 por unidad. Cada unidad consta de una acci贸n ordinaria y un warrant, siendo los warrants ejercitables a $2.05 por acci贸n hasta el 13 de agosto de 2028.
La compa帽铆a utilizar谩 los fondos para fines corporativos generales y capital de trabajo, incluidos objetivos operativos e I+D. Adem谩s, se emitieron 2,439 acciones administrativas a un tercero por servicios relacionados con la colocaci贸n. Todos los valores est谩n sujetos a un periodo de retenci贸n de cuatro meses que finaliza el 14 de diciembre de 2025.
Onco-Innovations (OTCQB:ONNVF)電� 鞚挫爠鞐� 瓿奠頃� 欷戧皽鞚� 鞐嗢澊 歆勴枆霅� 靷 氚滍枆鞚� 靹标车鞝侅溂搿� 毵堦皭頃橃棳 243,903雼渼毳� 雼渼雼� $1.64鞐� 氚滍枆頃� $400,000毳� 臁半嫭頄堨姷雼堧嫟. 臧� 雼渼電� 氤错喌欤� 1欤检檧 鞗岆煱韸� 1臧滊 甑劚霅橂┌, 鞗岆煱韸鸽姅 欤茧嫻 $2.05鞐� 2028雲� 8鞗� 13鞚缄箤歆� 頄夓偓頃� 靾� 鞛堨姷雼堧嫟.
須岇偓電� 臁半嫭 鞛愱笀鞚� 鞖挫榿 氚� 鞐瓣惮臧滊皽鞚� 韽暔頃� 鞚茧皹 氩曥澑 氇╈爜瓿� 鞖挫爠鞛愲掣鞙茧 靷毄頃� 鞓堨爼鞛呺媹雼�. 霕愴暅 氚滍枆 甏�霠� 靹滊箘鞀れ棎 雽�頃� 鞝�3鞛愳棎瓴� 2,439欤检潣 甏�毽＜鞁�鞚� 氚滍枆頄堨姷雼堧嫟. 氇摖 歃濌秾鞐愲姅 2025雲� 12鞗� 14鞚检棎 膦呺霅橂姅 4臧滌洈臧勳潣 氤错樃鞓堨垬 旮瓣皠鞚� 鞝侅毄霅╇媹雼�.
Onco-Innovations (OTCQB:ONNVF) a cl么tur茅 avec succ猫s son placement priv茅 non-interm茅diaire pr茅c茅demment annonc茅, levant 400 000 $ par l'茅mission de 243 903 unit茅s 脿 1,64 $ par unit茅. Chaque unit茅 comprend une action ordinaire et un warrant, les warrants 茅tant exer莽ables 脿 2,05 $ par action jusqu'au 13 ao没t 2028.
La soci茅t茅 utilisera les fonds pour des besoins g茅n茅raux de l'entreprise et le fonds de roulement, y compris des objectifs op茅rationnels et de R&D. De plus, 2 439 actions administratives ont 茅t茅 茅mises 脿 un tiers pour des services li茅s au placement. Tous les titres sont soumis 脿 une p茅riode de blocage de quatre mois prenant fin le 14 d茅cembre 2025.
Onco-Innovations (OTCQB:ONNVF) hat die zuvor angek眉ndigte, ohne Makler durchgef眉hrte Privatplatzierung erfolgreich abgeschlossen und dabei $400.000 durch die Ausgabe von 243.903 Einheiten zu je $1,64 pro Einheit eingenommen. Jede Einheit besteht aus einer Stammaktie und einem Warrant; die Warrants sind zum Preis von $2,05 pro Aktie bis zum 13. August 2028 aus眉bbar.
Die Gesellschaft verwendet die Mittel f眉r allgemeine Unternehmenszwecke und zur Deckung des Umlaufverm枚gens, einschlie脽lich operativer Ziele und F&E. Zus盲tzlich wurden einem Dritten zur Verg眉tung f眉r mit der Platzierung verbundene Leistungen 2.439 Verwaltungsaktien ausgegeben. Alle Wertpapiere unterliegen einer viermonatigen Haltefrist, die am 14. Dezember 2025 endet.
- None.
- Potential dilution to existing shareholders
- Small offering size may indicate limited investor interest
Not for distribution to United States wire services or for dissemination in the United States
VANCOUVER, BC / / August 13, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that it has closed its previously-announced (see news release dated July 29, 2025) non-brokered private placement (the "Private Placement") of 243,903 units of the Company (the "Units") at a price of
The proceeds from the Private Placement will be used for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives.
The Company has also issued 2,439 Shares ("Administrative Shares") of the Company to an arm's-length third party, in consideration for administrative services rendered in connection with the Private Placement.
Pursuant to applicable securities laws, all securities issued under the Private Placement and the Administrative Shares will be subject to a statutory hold period of four months and one day, expiring on December 14, 2025.
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated closing date, use of proceeds and anticipated proceeds thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be far lower than expected, that the proceeds therefrom may be used other than as currently contemplated, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original on ACCESS Newswire
FAQ
How much did Onco-Innovations (ONNVF) raise in its August 2025 private placement?
What are the terms of ONNVF's August 2025 private placement warrants?
When does the hold period expire for Onco-Innovations' August 2025 private placement securities?
How will Onco-Innovations use the proceeds from its August 2025 private placement?
